Detailed Narrative
Strong Financial Performance in Q3 and 9M FY26
NephroPlus delivered robust financial results for Q3 and 9M FY26. Q3 FY26 revenue increased 32% year-on-year to Rs. 260 crores, while 9M FY26 revenue grew 37% to Rs. 733 crores. Adjusted EBITDA for Q3 FY26 was Rs. 63 crores, up 43.1% YoY, with margins expanding to 24.3%. For the nine-month period, adjusted EBITDA reached Rs. 175 crores, a 52% YoY growth, with margins improving to 23.9%. Adjusted PAT also saw significant growth, rising 71% in Q3 to Rs. 34 crores and 103.3% in 9M to Rs. 86 crores.
Operational Growth Driven by Patient and Treatment Volumes
Operational metrics demonstrated consistent growth, with patient volumes for 9M FY26 reaching over 36,550, a 15% increase year-on-year. Treatment volumes in Q3 FY26 stood at 0.98 million, up 17.7% from the previous year, and 9M FY26 treatments totaled 2.85 million, growing 17% YoY. Revenue per treatment (RPT) also improved, with Q3 FY26 RPT at Rs. 2,642 (up 12% YoY) and 9M FY26 RPT at Rs. 2,574 (up 17% YoY), primarily driven by increasing penetration into higher-priced international markets.
Strategic Expansion and International Contribution
The company's strategy of international expansion has significantly impacted its revenue mix, with international revenues contributing approximately 41% of total revenue in 9M FY26, a substantial increase from 12% in FY23. NephroPlus has established a strong presence in the Philippines, becoming the third-largest network, and secured a PPP project in Uzbekistan. New market entries are evaluated based on demand, reimbursement, political stability, and ROCE accretiveness, with a target of entering 1-2 new geographies every 1-2 years.
Focus on ROCE and Capital Allocation
NephroPlus maintains a strong focus on Return on Capital Employed (ROCE) as a primary filter for capital allocation decisions. The annualized ROCE is projected to be 24.7% in FY26, a significant improvement from 18.7% in FY25. The company's net debt remained negative at Rs. 283.6 crores as of 9M FY26, indicating a healthy surplus cash position. Historically, capital expenditure has typically ranged between Rs. 100-125 crores, with a consistent focus on cash conversion, reflected in a 65% operating cash flow to EBITDA conversion for 9M FY26.
India Platform and Cost Efficiency
The company's 16 years of operating in India at a low price point (around $20 RPT) has enabled it to build an efficient platform. This includes direct negotiation with global suppliers for consumables, optimal human resource staffing through training academies (10 in India), an in-house biomedical team for preventive maintenance and machine life extension, and technology for network management. These efficiencies contribute to higher margins in international markets compared to local competition.
Business Model and Growth Drivers
NephroPlus operates through captive (shop-in-shop with hospitals), PPP, and standalone clinic models. The captive model is the largest component in India, followed by PPPs, which are pursued opportunistically. Standalone clinics are a small but growing component. Growth is expected from ramping up existing clinics, roll-ups of clinics in existing countries (Brownfield acquisitions), and strategic entry into new countries or large PPP projects. The company aims for a revenue CAGR of 15%-20% over the next 3-4 years, while acknowledging the unpredictable nature of large-scale growth initiatives.